Antiretroviral Therapy News

• Nearly Half of HIV PrEP Descovy Switches Contraindicated For nearly 2 years, a newer and more expensive version of the first HIV prevention pill has been available to people who can benefit. Should you prescribe it?
  Medscape Medical News, September 22, 2021
• COVID-19 Causes Major Interruption in Global HIV Progress From testing to treatment, Global Fund HIV services have been hampered by COVID-19. But US providers shouldn't rest on their laurels either.
  Medscape Medical News, September 21, 2021
• ESMO 2021 Survival Benefit With Pembro in TNBC, but Only for Subgroup New results show a survival benefit in a subgroup of women with triple-negative breast cancer (TNBC) when pembrolizumab (Keytruda) is added to chemotherapy.
  Medscape Medical News, September 21, 2021
• ESMO 2021 Androgen Deprivation Alone No Longer Acceptable for mCSPC Androgen deprivation alone is no longer an acceptable option for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), experts contend.
  Medscape Medical News, September 20, 2021
• ICS 2021 csDMARDs Could Add to TNF Inhibitors' Benefits in SpA EuroSpA Research Collaboration data hint at better retention and remission rates with csDMARD-TNFi cotherapy vs TNFi alone in spondyloarthritis.
  Medscape Medical News, September 16, 2021
• Immunotherapy for Cancer Patients With Poor PS Needs a Rethink Use of check point inhibitors for patients with advanced cancer who have poor performance status (PS) needs a rethink, says editorialists.
  Medscape Medical News, September 16, 2021
• HIV Tied to Higher Risk of Sudden Cardiac Death HIV infection was associated with a greater risk of sudden cardiac death (SCD) in an observational study, especially among those with poor HIV disease control and/or a high burden of SCD risk factors.
  Reuters Health Information, September 15, 2021
• Severe Skin Reactions With Enfortumab Vedotin Approved for metastatic urothelial cancer, the drug has now been associated with cases of severe skins reactions, some of which have been fatal.
  Medscape Medical News, September 15, 2021
• Rheumatologists Report Breakthrough COVID, Booster Studies First reports of breakthrough COVID in fully or partially vaccinated patients with RMDs hint at encouraging low rates of infection post vaccination, and a small series supports booster shots.
  Medscape Medical News, September 13, 2021
• WCLC 2021 Unequal Resource Distribution Underlies Lung Cancer Disparities Lung cancer disparities are reversible, but it will take changes at the social policy and organizational levels to do it, says experts.
  Medscape Medical News, September 13, 2021
• WCLC 2021 POSEIDON: Two ICIs Plus Chemo Up Survival in mNSCLC Patiehts with stage IV non–small cell lung cancer have better outcomes when tremelimumab is added to durvalumab and chemo, a phase 3 trial shows, but questions remain over the role of anti-CTLA-4 agents.
  Medscape Medical News, September 10, 2021
• ESMO 2021: Impressive Clinical Research Despite Pandemic At the forthcoming annual meeting of the European Society for Medical Oncology, the strength and depth of clinical research despite disruptions caused by the pandemic are sure to impress, says an expert.
  Medscape Medical News, September 09, 2021
• ESC 2021 STOP-DAPT 2 ACS: 1 Month of DAPT Inadequate After Recent ACS Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT in patients undergoing PCI after acute coronary syndrome.
  Medscape Medical News, September 03, 2021
• Pfizer, Merck Launch New Trials of Oral COVID-19 Drugs Pfizer and Merck announced on Wednesday new trials of their experimental oral antiviral drugs for COVID-19 as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.
  Reuters Health Information, September 01, 2021
• AACP 2021 Neuropsychiatry Affects Pediatric OCD Treatment As treatment of pediatric obsessive-compulsive disorder (OCD) has evolved in recent years, more attention is being given to the neuropsychiatric underpinnings of the condition.
  Medscape Medical News, September 01, 2021
• AUA Updates LUTS/BPH Guidelines on Initial Workup, Surgery This new version includes updated information regarding the use of beta 3 agonists and phosphodiesterase-5 (PDE5) inhibitors. The authors also weigh in on natural therapies.
  Medscape Medical News, September 01, 2021
• Study: More Than Half of People Taking HIV PrEP Discontinue Use Using EHR records of 13,900 adults linked to HIV pre-exposure prophylaxis, researchers found that patients were most likely to stop using PrEP within the first 2 years of receiving the prescription.
  Medscape Medical News, August 26, 2021
• Review Eyes Nail Toxicities Related to Targeted Cancer Therapy The investigators found that paronychia and periungual pyogenic granulomas were the most common nail unit toxicities caused by targeted therapy.
  Medscape Medical News, August 24, 2021
• SGLT2 Inhibitor Use Rising in Diabetic Kidney Disease 'SGLT2 inhibitors are here to stay as a new standard of care for patients with diabetic kidney disease,' said Dr Katherine Tuttle, a nephrologist at Providence Healthcare in Spokane, Washington.
  Medscape Medical News, August 24, 2021
• HIV+ Individuals on ART in Africa More Often Adhere to Short-Course TB Prophylaxis Tuberculosis preventive therapy completion rates were higher for short-course isoniazid-rifapentine than for isoniazid alone among individuals with HIV on antiretroviral therapy in Africa, a randomized trial shows.
  Reuters Health Information, August 23, 2021
• PrEP Tied to Renal Impairment in With Advanced Age, Pre-existing Renal Dysfunction Adults taking HIV pre-exposure prophylaxis (PrEP) have an overall low risk of renal impairment, but a new study suggests that risk is greater for people over age 50 and those with pre-existing renal dysfunction.
  Reuters Health Information, August 19, 2021